Presented by Ralph Hughes, VP at PharmaVentures, the webinar looks at the importance of Market Access in Dealmaking.
What does this webinar address?
Market Access has a direct impact on the value of an asset and therefore impacts deal terms in any licensing deal. Companies often overlook Market Access of their drug candidates when looking for partners which puts them in a weak position when negotiating their deals.
How Small/Mid-Size Firms are Shaping the Healthcare M&A Market
Access Request
PharmaVentures partnered with Informa to deliver a live panel discussion . It is now available to watch on demand.
Chaired by Dr Fintan Walton, CEO and Founder of PharmaVentures, the webinar took the form of a panel discussion with:
Jonathan Seaton, Head of Corporate Business Development, Bio-Rad
Dr Paul MacLeman, Professional Company Director
Dr Adrian Dawkes, Managing Director, PharmaVentures
Dr Jansen Jacob, Vice President, PharmaVentures
What does this webinar address?
Whilst the mega deals make the headlines, it is the smaller companies who are shaping the M&A landscape with their interesting and innovative deals. They have the drive and efficiencies that allow them to do deals more quickly.
In this webinar, the panel brought its unique insight into the issues, challenges, and benefits of doing M&A deals amongst small to mid-sized Diagnostics, MedTech, CDMO & CRO companies.
Watch to learn the answers to the following
Why are strategic thinking and preparation key to success?
How do you avoid failure in doing M&A?
What are the key drivers for companies taking the M&A route?
What are key lessons from selling and buying businesses?
What negotiation tactics work?
How important is the asset vs the people in acquiring a business?
PharmaVentures partnered with Informa to deliver a live panel discussion during CPhI Worldwide in the form of a webinar.
This webinar focuses on the future of broader outsourced contract services in the Pharmaceutical Industry, which spans the Contract Development Manufacturing Sector (primary and secondary) that includes specialised biologics, excipients, fine chemicals and drug delivery, through to clinical research organisations, contract sales and more advisory based service offerings such as CMC and regulatory affairs.
Chaired by Dr Fintan Walton, CEO & Founder of PharmaVentures, the panel included:
Mark Bamforth, Exec. Chair and CEO, ArrantaBio
Amit Karna, Partner, Keensight Capital
Dr Thomas Dobmeyer, CEO, PharmaLex
Mark Andrews, Managing Director, PharmaVentures
Topics discussed:
What’s shaping the future of the outsourcing industry?
Will it remain fragmented or more consolidated?
What is the outcome for the pharmaceutical industry?
To what extent is private equity investment changing the outsourcing services business?
What will the pharmaceutical services industry look like in 5 years?
Who should watch? Senior executives, decision makers and influencers within biopharmaceutical companies, CROs, CDMOs, Consultancies, Private Equity and Venture Capital.
Watch: What is driving consolidation in the pharmaceutical contract services industry?
Vaccines are considered to be one of the greatest public health achievements of the last century, so when the COVID-19 pandemic brought the world to a stop, all energies were focused on bringing a vaccine to market.
With multiple vaccines now approved and being manufactured in record time, we celebrate this accelerated pace of development in the field. Exploring the different vaccine technologies to understand their mode of action, benefits, risks, and potential real-life impact on protection. The challenges in manufacturing enough doses to vaccinate the world and the potential impact the WTO’s IP waiver proposal will have on future innovation.
Discussion Points:
Vaccine Science: Two Centuries of Continuous Research, Improvements, and Achievements
Future Potential of mRNA
Where are the facilities equipped for these new molecule types? What problems are arising and how is the industry working to fix them?
Vaccinating the world, a look at WTO’s proposed IP waiver and what it could mean for future innovation
Leonard Friedland, Vice President, Director Scientific Affairs and Public Health, GSK Vaccines
Fiona Barry, Associate Editor, Global Data
Dr Fintan Walton, CEO of PharmaVentures
Watch: Innovation in the Race to Develop COVID-19 Vaccines
Access Request
△ Legitimate business purposes include contacting me regarding PharmaVentures’ services, commercial opportunities in M&A, Licensing, Fundraising or similar on behalf of their clients or sending me marketing material related to relevant third-party events, products and services.
For further information on how PharmaVentures processes your data, please view our Privacy page.
A conversation with Fintan Walton, Founder of PharmaVentures
Tony Jones, Chief Executive of One Nucleus, caught up with Fintan Walton to discuss the evolution of the deal making processes, where it is going in the future and what role PharmaVentures plays in deal making to support clients globally.
This insightful interview is useful to those new to deal making, but also interesting viewing for experienced deal makers who may recognise some of the situations they discuss, hard lessons from 30 years of experience.
How to achieve success in deal making
Learn the 3 key things you need in a successful transaction
What is the emotional aspect of deal making and what does the negotiator need to understand and recognise when they enter the meeting room?
How do you meet the biotech challenge – getting your voice heard by key decision makers within the pharmaceutical companies?
What are the key drivers for pharmaceutical companies when doing deals?
Gain insight into preparations for due diligence and negotiation
Hard lessons from 30 years of experience
Find out how the structures, dynamics and trends within deal making have evolved and how the marketplace has changed
Gain insight into how PharmaVentures’ experience and the time invested by the team to get to know their clients, makes a difference to the deal outcome
Understanding culture, language and having the experience for successful global deal making – critical resources PharmaVentures provides for its clients
Discover how PharmaVentures opens the doors for clients and how diversity within the team enables the company to reach out across cultures
When does PharmaVentures get into the valuation discussion on behalf of a client?
How to achieve success in deal making
Access Request
△ Legitimate business purposes include contacting me regarding PharmaVentures’ services, commercial opportunities in M&A, Licensing, Fundraising or similar on behalf of their clients or sending me marketing material related to relevant third-party events, products and services.
For further information on how PharmaVentures processes your data, please view our Privacy page.
Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape.
Partnerships and mergers are a key tool for adding value to pharmaceutical companies; helping to navigate technological limitations, address portfolio challenges and chase innovation.
This webinar, delivered in partnership with PharmaVentures, examines the trends and developments driving deal-making in the current market.
Chaired by Dr Fintan Walton, CEO & Founder of PharmaVentures, the panel included:
John P. FitzGerald, Senior Director, Business Development & Acquisitions, Abbvie
Andreas Raabe, Managing Partner & Founder, Adragos Pharma
William S. Marth, Managing Partner, North Ocean Ventures
Jansen Jacob, Vice President, PharmaVentures
Ozgur Akbulut, Director – Global Divestments and Contract Manufacturing Lead, Takeda
What the audience said:
“Great discussion, I wish it was 2 hours.”
“Thanks for the discussion, I also had the feeling we were just starting, so time flew by quickly! Very interesting and very professional speakers. Thanks.”
Watch: How is M&A Shifting the Pharma Manufacturing Landscape?
Having advised on the strategic direction of over 40 sites globally, we can help you to divest your manufacturing operations whilst safeguarding security of supply and retaining jobs, and assisting the new owners to build and grow profitable new businesses.
Our strategic reviews of operations have enabled our clients to engage us in the successful divestment of sites covering both small molecule and biologics capabilities across the globe.
